Survival Rate Up to 100% for Late Stage Treatment of Anthrax Infections

GRONINGEN, The Netherlands, June 22, 2010/PRNewswire/ -- IQ
Therapeutics B.V., Groningen, the Netherlands, announced this week
that in collaboration with the University of Texas Medical Branch
it has obtained outstanding results for the treatment of inhalation
anthrax. In a rabbit model up to 100% survival could be achieved
with extended time to treatment (48h post infection) with a
combination of two specific monoclonal antibodies developed by IQ
Therapeutics. This has significant potential for saving lives of
infected people who have no immediate access to treatment.

IQ Therapeutics' Chief Scientific Officer Herman Groen states:
"The results obtained in the recent studies are unprecedented. We
have demonstrated in a rabbit model that we can achieve up to 100%
survival after treatment with a single dose of two antibodies
(anti-PA and anti-LF), at 48 hours after the infection. Our
advanced stage treatment is unique and has a tremendous advantage
in real life settings where an infected person might not
immediately be aware of the infection or does not have immediate
access to proper treatment. Especially in those cases, IQ
Therapeutics' dual antibody approach can in the future help saving
lives, as there is currently no cure available for that stage of
disease."

High survival rates with the Dual Antibody Approach (a
combination of fully human anti-PA and anti-LF antibodies) have
been demonstrated before. However, with the help of Dr. Peterson
and his group at the University of Texas Medical Branch (UTMB),
several efficacious dose combinations could be established that
showed 100% survival.

With the efficacy milestone completed, IQ's development of the
Dual Antibody Approach will now focus on additional confirmation,
human safety and advanced development studies.

Anthrax is an acute infectious disease caused by the
spore-forming bacterium Bacillus anthracis. Inhalational anthrax is
often fatal if not treated immediately with the proper medication,
before symptoms have appeared. IQ Therapeutics is focusing on
treatment of patients who have become symptomatic and could
otherwise not be saved with antibiotics. IQ developed the "Dual
Antibody Approach", using a combination of two monoclonal
antibodies targeting the toxin produced by the Bacillus anthracis.
The efficacy of DAA is being examined in preclinical challenge
studies performed by the group of Dr. Peterson (UTMB), through a
screening contract from the National Institute of Allergies and
Infectious Diseases, part of National Institutes of Health.

IQ Therapeutics

IQ Therapeutics BV is a human antibody technology company based
in Groningen, The Netherlands. Its mission is to develop instant
immunity for healthcare threats, through the development its
Instant Immunity(TM) for therapeutic applications in biodefense,
infectious diseases and oncology. The company is applying its
Cloning the Human Response(TM) technology for its pipeline and
third parties' to generate and develop fully human antibodies from
immunized or vaccinated donors for the prevention and treatment of
infectious diseases. IQ Therapeutics is a spin-out of the life
science company IQ Corporation BV.